Watch News 8 at 5:30pm

Remdesivir helps coronavirus patients recover faster, clinical trial finds


HARTFORD, Conn. (WTNH) — Remdesivir — originally used to fight Ebola — is now helping with moderate to severe COVID-19 cases.

Officials said the drug is allowing patients to say in the hospital fewer days and that recovery is 31% faster, according to an NIH clinical trial

“The data shows that Remdesivir has a clear cut, significant positive effect in diminishing the time to recover,” said Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases. “This is really quite important.”

Fauci said it has proven that a drug can block the virus, and staff at Hartford HealthCare said they’re seeing positive results.

“Remdesivir is a very, very promising drug,” said Keith Grant, Senior Systems Director for Infection Prevention. “This is a drug we’re very much aware of, and we’re using, and the capability and capacity of usage is something that we’ve not just now since that study, but before now, we’ve been looking at.

However, Kenneth Robinson, Chief of Department of Emergency Medicine, said people should not let their guards down and should keep social distancing.

“We’re still at a really high plateau,” Robinson said of the state coronavirus peak. “In fact, today, we have more patients admitted to Hartford Hospital than we did yesterday who are COVID or COVID suspected.

Copyright 2020 Nexstar Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Amazon delivery van stolen in Hartford, one suspect still at large after crashing through fence

News /

Southington HS going remote on Monday after COVID causes staffing shortage

News /

More than 650K absentee ballots in CT have yet to be returned

News /

More than 650K absentee ballots in CT have yet to be returned

News /

Man injured, suspect at large after shooting on Rt. 5 in South Windsor

News /

National Prescription Drug Take-Back Day Helping CT's Opioid Crisis

News /
More Hartford

Trending Stories

Don't Miss

More Don't Miss